FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.235,50 +149,70 (+0,39%) Nasdaq
15.924,80 +313,04 (+2,01%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,97 +0,40 (+0,48%) Bitcoin EUR
59.531,50 -435,26 (-0,73%)
Alimera Sciences, Inc. (ALIM)
| Chiusura precedente | 3,3100 |
| Aperto | 3,2800 |
| Denaro | 2,4900 x 200 |
| Lettera | 4,2700 x 200 |
| Min-Max giorno | 3,2800 - 3,4801 |
| Intervallo di 52 settimane | 1,5600 - 4,3800 |
| Volume | |
| Media Volume | 72.064 |
| Capitalizzazione | 180,623M |
| Beta (5 anni mensile) | 1,20 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,8400 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 8,00 |
GlobeNewswireAlimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update
Conference Call to be held the same day at 9:00am Eastern TimeATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report third quarter financial results on October 26, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the
- GlobeNewswire
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg and YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg will be featured in five presentations during the Retina Society’s 56th An
GlobeNewswireAlimera Sciences Appoints Jason Werner as Chief Operating Officer
Dr. Philip Ashman Appointed as President of International Operations Jason Werner, COO, Alimera Sciences Jason Werner, COO, Alimera Sciences ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer (“COO”), effective O
